, it is possible that apparent increases in PTH are attributable to fragment detection, i.e., fragments unique to the degradation process in EDTA plasma; no such increase is observed in serum samples. Reassuringly, the increase is modest and of questionable clinical consequence.
Anti-Actin Antibodies in Celiac Disease
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3 Pediatric Gastroenterology, "Di Cristina" Hospital of Palermo, Palermo, Italy; * address correspondence to this author at: Internal Medicine, University Hospital of Palermo, via del Vespro 141, 90127 Palermo, Italy; fax 39-091-6552936, e-mail acarroccio@hotmail.com) marker of severe intestinal villus atrophy (1 ) . AAAs have been detected with an immunofluorescence (IF) technique and seem to contribute to villus cytoskeleton damage and to the pathogenesis of intestinal damage in CD (2 ) .
The aims of the present study were to evaluate the relationship between the presence of serum IgA AAAs and severity of intestinal mucosa damage in CD patients and to compare the IF assay with a new ELISA for IgA AAA determination.
We enrolled 150 individuals in the study. IgA AAAs were assayed in 58 consecutive CD patients diagnosed between January and December 2003: 30 adults (10 male; median age, 32 years; range, 18 -56 years) and 28 children (14 male; median age, 18 months; range, 1-12 years). The sera were collected at CD diagnosis, after overnight fasting, and were frozen at Ϫ80°C for a mean of 9 months before AAA determination. In 20 patients, AAAs were reassayed after 6 -12 months of gluten-free diet. CD diagnosis was based on the revised criteria of the European Society of Pediatric Gastroenterology and Nutrition (3 ). We enrolled 64 patients as "healthy" controls [34 adults evaluated for suspected hypercholesterolemia (15 male; median age, 35 years; range, 18 -56) and 30 children with recurrent pharyngotonsilitis (14 male; median age, 3 years; range, 1-12 years)]. None of these controls had symptoms or laboratory signs suggesting CD, and all were negative for anti-endomysium (EmA) and antitransglutaminase (anti-tTG). We enrolled an additional 28 adults with autoimmune or gastrointestinal diseases other than CD as "disease" controls: type 1 autoimmune hepatitis (AH; 6 cases), type 2 AH (4 cases), systemic lupus erythematosus (4 cases), Sjö gren disease (3), primary biliary cirrhosis (2), Crohn disease (4), multiple food intolerance (3), autoimmune enteropathy (1), and refractory sprue (1) .
Finally, to test whether the anti-actin ELISA used was specific for F-actin, we assayed for IgG anti-F-actin in 18 sera from patients with type 1 AH, positive by IF for IgG anti-F-actin on HEP-2 cells (titer range, 1:160 -1:1280), and 30 negative sera from healthy controls.
EmAs were assayed on human umbilical cord by IF (4 ). The anti-tTG ELISA was performed with commercial reagents with recombinant human tTG as the antigen (5 We added 100 L of diluted serum (1:101) to the wells and incubated for 30 min at room temperature. After the wells were washed three times with buffer, 100 L of the IgA conjugate was added to each well, and the plates were incubated for 30 min and washed again. We added 100 L of 3,3Ј,5,5Ј-tetramethylbenzidine (TMB) chromogen to each well and incubated the wells in the dark for 30 min at room temperature. Stopped reactions were read at 450 and 620 nm. The typical threshold value for AAA absorbance was arbitrarily fixed as equal to the mean value ϩ 2 SD displayed by control sera (0.270). The control wells (no serum) introduced in each plate had an absorbance of Ͻ0.025. Intra-and interassay CV were calculated on 20 samples. Three biopsy specimens of the second part of the duodenum were obtained (5, 6 ) ; slides were stained with hematoxylin and eosin and graded by conventional histology according to Oberhuber et al. Intestinal histology of the CD patients revealed that 8 had mild villus atrophy, 23 had marked villus atrophy, and 27 had total villus atrophy. All patients with marked or total villus atrophy were positive for AAAs in the ELISA, whereas all 7 patients negative for AAA had mild villus atrophy. There was a significant inverse correlation between AAA values by ELISA and IF and the villusheight/crypt-depth ratio (r ϭ Ϫ0.447 by ELISA, r ϭ Ϫ0.404 by IF; P Ͻ0.0001; Fig. 1 ). Furthermore, the CD patients negative for AAAs by ELISA had significantly higher villus/crypt ratios than the patients positive for AAAs [mean (SD), 1.41 (0.32) vs 0.52 (0.15); P Ͻ0.01].
Anti
In 19 of the 20 CD patients, AAA assay results were negative, by both ELISA and IF, after 6 -12 months on gluten-free diet.
IgG AAA results were positive by ELISA (absorbance range, 0.300 -0.935) in 17 of the 18 patients with type 1 AH showing anti-F-actin antibodies with IF, whereas none of samples from healthy controls gave positive results.
Gluten ingestion in CD is associated with alterations of the intestinal mucosa and interactions between gliadin and several extracellular matrix components, leading to the formation of neo-epitopes, which act as autoantigens (8, 9 ) . AAAs, described in CD very recently (1 ), are among the autoantibodies consequent to the formation of these autoantigens in CD patients.
Our results show that AAAs correlate with severity of intestinal villus damage in CD patients: The AAA ELISA was positive in 51 of the 58 CD patients studied, and all patients with severe intestinal mucosa damage were positive for AAAs. The 7 patients negative for AAAs had mild villus atrophy. Furthermore, there was a highly significant inverse correlation between AAA values (assayed both by ELISA and IF) and the villus/crypt ratios in CD patients. A similar correlation coefficient (0.56) between AAA titers and severity of intestinal mucosa lesions has been reported in a multicenter study on the usefulness of AAA assays in CD (10 ) .
Both AAA assays (IF and ELISA) were also positive in several disease controls, mainly in patients with type 1 AH and primary biliary cirrhosis. In general, the ELISA for IgA AAAs that we used in the present study showed good reproducibility and a higher sensitivity than the previously described ELISAs (1, 11, 12 ) , and its use can be recommended. This probably depends on the use of F-actin and not G-actin as antigen in the ELISA: In vitro incubation of intestinal epithelial cells with gliadin caused intracellular actin polymerization with an increase in F-actin (2 ), which is the real neo-epitope recognized by AAAs. The major problem in using an F-actin ELISA is the difficulty of getting, in vitro, 100% of actin in its polymerized form (F-actin) and avoiding the unpolymerized form (G-actin), which could interfere with the quality of the test. However, the materials we used seemed to be specific for F-actin antibodies as 17 of the 18 patients with type 1 AH and none of the controls were IgG AAApositive with the ELISA. Additional studies involving a greater number of anti-F-actin-positive patients are needed to confirm this result.
In conclusion, AAAs are a reliable marker of severe intestinal mucosa damage in CD patients, and a simple ELISA technique offers an accurate method for their determination. We propose that, after exclusion of coexistent CD and type 1 AH, intestinal biopsy is not necessary for villus/crypt evaluation in EmA/AAA-positive patients.
We are indebted to Professor A. Craxì and his research group (Gastroenterology Division of Palermo University, Palermo, Italy), who provided the stored sera from patients suffering from type 1 AH. We thank Carole Greenall for excellent revision of the English. We are particularly grateful to M.G. Clemente (Pediatric Department, Cagliari University, Italy) for technical advice on the AAA IF assay. We also thank C. Scalici and G. Di Fede for assistance in revising the manuscript. Handling and directly sampling from primary barcodelabeled pediatric tubes is a challenge for laboratories receiving substantial numbers of samples from pediatric patients (1 ). To prevent iatrogenic anemia from frequent blood draws, preanalytical as well as analytical systems should be capable of handling small sample volumes collected in pediatric tubes (2 ) . However, most analyzers and robotic systems have been developed for standard 5-to 7-mL test tubes and cannot handle small pediatric tubes. This incompatibility leads to manual processing of pediatric samples and transfer of samples to micro cups even in large automated laboratories. Manual handling of specimens and transfer of samples are laborious and may lead to errors in both the preanalytical and analytical phases.
In most hospitals, blood of pediatric patients is collected in small pediatric tubes by heel puncture, in contrast to adult patients from whom blood is collected by venipuncture in 5-to 7-mL evacuated tubes. Although most instruments require that the barcode label be applied vertically for reading, regular barcode labels do not conveniently fit on small pediatric tubes (2 ) . Because of the reduced size of the tubes, separate buckets are needed for centrifugation, and often the barcode labels, which are too large for the small tubes, interfere with proper fitting in the buckets; they can also get damaged and no longer be readable (1 ) . Furthermore, standard analyzer sample racks and trays do not support the dimensions of pediatric tubes. The same holds for tube carriers used by various work cells and track systems.
In our clinical chemistry department, we receive ϳ2500 test tubes daily from various departments of the University Medical Center in Utrecht, The Netherlands. Among these tubes, ϳ500 pediatric tubes are derived from the pediatric hospital that is part of our organization. Until recently, these tubes were analyzed in a separate satellite laboratory in the pediatric hospital. For efficiency reasons, chemistry tests previously performed in the pediatric hospital, ϳ250 tubes per day, were moved to our central laboratory, in which two Vitros 950 and one Vitros 250 dry chemistry analyzers (Ortho Clinical Diagnostics) are integrated into an enGen TM work cell (Thermo Electron Corporation). This work cell includes an entry/exit module where samples can be loaded and unloaded. A robotic arm picks up the tubes from sample blocks placed in 1 of the 3 entry drawers and puts each tube in an individual carrier. The barcode is read, and the information is written to a chip in the base of the carrier. The computer uses the requested tests and the status of the different analyzers to calculate an optimal route for each tube through the work cell to the analyzers. Tubes with a cap are first routed to the decapper. After completion of all requested tests, the tubes are sent to the entry/exit module again, where the tubes are placed in barcode-labeled storage racks. These storage racks can be placed directly in the refrigerator. If a tube is needed, for example for additional tests, the data manager will identify at which position in which block the tube is located.
To be able to handle pediatric tubes through the whole preanalytical and analytical phase in a way similar to that for the standard 5-to 7-mL tubes, our laboratory has made the following adjustments. Before blood drawing at the pediatric hospital, 500-L Capiject lithium-heparin pediatric gel tubes (Terumo Capiject System; Omnilabo) are prefixed in Microtainer tube extenders (Becton Dickinson; Fig. 1A ), which make handling of the tubes during blood drawing easier. More importantly, the tube extenders make possible uniformity in size of both pediatric and adult specimens. As a result, the regular barcode labels can be placed in the usual vertical position on the primary pediatric tubes and be transported in standard racks (Fig.  1B) . The pediatric tubes are centrifuged together with the standard tubes in the same buckets and centrifuge. Because the sample probe senses the liquid height and starts sampling just below the surface, the Vitros analyzers can deal with variable liquid heights in different sample tubes. However, to enable pipetting directly from these primary barcode-labeled pediatric tubes, the speed at which the sample probe is lowered had to be increased because the fluid height drops more rapidly in these tubes during aspiration as a result of the smaller inner diameter.
